dummy, randomised, comparative phase III trial.
Lancet Oncol 2009;10:115–24.
24 Karthaus M et al. Efficacy and safety of oral
palonosetron compared with IV palonosetron
administered with dexamethasone for the
prevention of chemotherapy-induced nausea
and vomiting (CINV) in patients with solid tumors
receiving cisplatin-based highly emetogenic
chemotherapy (HEC). Support Care Cancer doi:
10.1007/s00520-015-2657-1.
25 Eisenberg P et al. Improved prevention of
moderately emetogenic chemotherapy-induced
nausea and vomiting with palonosetron,
a pharmacologically novel 5HT3 receptor
antagonist: results of a phase III, single-
dose trial versus dolasetron. Cancer
2003;98(11):2473–82.
26 Gonullu G et al. Electrocardiographic findings
of palonosetron in cancer patients. Support Care
Cancer 2012;20(7):1435–9.
27 Yavas C et al. Acute effect of palonosetron
on electrocardiographic parameters in cancer
patients: a prospective study. Support Care
Cancer 2012;20(10):2343–7.
28 Tsavaris NB et al. Comparison of
different schedules of ondansetron (GR
38032F) administration during cisplatin-
based chemotherapy: a randomized trial.
Chemotherapy 1995;41(1):70–6.
29 Boccia M et al. Efficacy of oral palonosetron
compared to intravenous palonosetron for the
prevention of chemotherapy-induced nausea
and vomiting associated with moderately
emetogenic chemotherapy: a phase 3 trial.
Support Care Cancer. 2013;21(5):1453–60.
30 Ruffo P et al. Identification of factors
influencing chemotherapy-induced nausea and
vomiting (CINV) treatment compliance – results
from quantitative market research. ASCO 2016;
Abstr 165984.
31 Natale JJ et al. Drug-drug interaction
profile of components of a fixed combination of
netupitant and palonosetron: Review of clinical
data. J Oncol Pharm Pract 2016;22(3):485–95.
32 Thorn S et al. Effects of a fixed-dose
combination strategy on adherence and risk
factors in patients with or at high risk of CVD.
JAMA 2013;310(9):918–29.
33 Hesketh PJ et al. A review of NEPA, a
novel fixed antiemetic combination with the
potential for enhancing guideline adherence
and improving control of chemotherapy-
induced nausea and vomiting. Biomed Res Int
2015;2015:651879.
42 | 2018 | hospitalpharmacyeurope.com
34 Aapro M et al. A randomized phase III study
evaluating the efficacy and safety of NEPA,
a fixed-dose combination of netupitant and
palonosetron, for prevention of chemotherapy-
induced nausea and vomiting following
moderately emetogenic chemotherapy. Ann
Oncol 2014;25(7):1328–33.
35 Hesketh PJ et al. Efficacy and safety of
NEPA, an oral combination of netupitant and
palonosetron, for prevention of chemotherapy-
induced nausea and vomiting following highly
emetogenic chemotherapy: a randomized
dose-ranging pivotal study. Ann Oncol
2014;25:1340–6.
36 Gralla RJ et al. A phase III study evaluating
the safety and efficacy of NEPA, a fixed-dose
combination of netupitant and palonosetron,
for prevention of chemotherapy-induced
nausea and vomiting over repeated cycles of
chemotherapy. Ann Oncol 2014;25:1333–9.
37 Rugo HS et al. Efficacy of NEPA (netupitant/
palonosetron) across multiple cycles of
chemotherapy in breast cancer patients:
A subanalysis from two phase III trials. Breast
2017;33:76–82.
38 Aapro M et al. NEPA, a fixed oral combination
of netupitant and palonosetron, improves control
of chemotherapy-induced nausea and vomiting
(CINV) over multiple cycles of chemotherapy:
results of a randomized, double-blind, phase
3 trial versus oral palonosetron. Support Care
Cancer 2017;25(4):1127–35.
39 Lanzarotti C, Rossi G. Effect of netupitant,
a highly selective NK1 receptor antagonist,
on the pharmacokinetics of midazolam,
erythromycin, and dexamethasone. Supportive
Care Cancer 2013;21:2783–91.
40 Rapoport B et al. Safety and efficacy of
rolapitant for prevention of chemotherapy-
induced nausea and vomiting after
administration of cisplatin-based highly
emetogenic chemotherapy in patients with
cancer: two randomised, active-controlled,
double-blind, phase 3 trials. Lancet Oncol
2015;16(9):1079–89.
41 Schwartzberg L et al. Safety and efficacy
of rolapitant for prevention of chemotherapy-
induced nausea and vomiting after
administration of moderately emetogenic
chemotherapy or anthracycline and
cyclophosphamide regimens in patients with
cancer: a randomised, active-controlled,
double-blind, phase 3 trial. Lancet Oncol
2015;16(9):1071–8.